You are here: Industry Insights > chronic hepatitis C

News List

CFDA approves Gilead’s Sovaldi for chronic hepatitis C treatment pharmaceufical-technology
September 27, 2017
The China Food and Drug Administration (CFDA) has approved Gilead Sciences’ Sovaldi (sofosbuvir at 400mg) for the treatment of patients with chronic hepatitis C virus (HCV) infection.
China FDA approves country’s first all-oral regimen for chronic hepatitis C, Daklinza in combination cphi-online
May 02, 2017
Daklinza and Sunvepra combination approved for genotype 1b, the most common chronic hepatitis C (HCV) genotype in China; combination has a 91-99% cure rate.
Health Canada Grants Priority Review to AbbVie's Investigational Regimen of Glecaprevir/Pibrentasvir americanpharmaceuticalreview
February 06, 2017
AbbVie has submitted a New Drug Submission (NDS), and received priority review from Health Canada, for its investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) for the treatment of all major chronic hepatitis C viru